JP2019518046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518046A5 JP2019518046A5 JP2018565675A JP2018565675A JP2019518046A5 JP 2019518046 A5 JP2019518046 A5 JP 2019518046A5 JP 2018565675 A JP2018565675 A JP 2018565675A JP 2018565675 A JP2018565675 A JP 2018565675A JP 2019518046 A5 JP2019518046 A5 JP 2019518046A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ring
- alkyl
- aromatic
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 58
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 201000008827 tuberculosis Diseases 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims description 3
- 125000005647 linker group Chemical group 0.000 claims description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229910052717 sulfur Chemical group 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000002365 anti-tubercular Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- -1 eg fluoro atoms) Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16174719 | 2016-06-16 | ||
| EP16174719.1 | 2016-06-16 | ||
| PCT/EP2017/064652 WO2017216281A1 (en) | 2016-06-16 | 2017-06-15 | Heterocyclic compounds as antibacterials |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518046A JP2019518046A (ja) | 2019-06-27 |
| JP2019518046A5 true JP2019518046A5 (enExample) | 2020-08-13 |
Family
ID=56132837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565675A Pending JP2019518046A (ja) | 2016-06-16 | 2017-06-15 | 抗菌薬としての複素環式化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11179396B2 (enExample) |
| EP (1) | EP3472158A1 (enExample) |
| JP (1) | JP2019518046A (enExample) |
| KR (1) | KR20190017948A (enExample) |
| CN (1) | CN109476657A (enExample) |
| AU (1) | AU2017286368B2 (enExample) |
| BR (1) | BR112018076126A2 (enExample) |
| CA (1) | CA3026010A1 (enExample) |
| EA (1) | EA201990043A1 (enExample) |
| MA (1) | MA45377A (enExample) |
| MX (1) | MX2018015656A (enExample) |
| WO (1) | WO2017216281A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3316969T2 (ro) | 2015-07-02 | 2022-07-31 | Janssen Sciences Ireland Unlimited Co | Compuși antibacterieni |
| PE20181352A1 (es) | 2015-09-17 | 2018-08-22 | Marvin J Miller | Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias |
| MA45377A (fr) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Co | Composés hétérocycliques en tant qu'agents antibacteriens |
| MA47676A (fr) | 2017-03-01 | 2021-06-02 | Janssen Sciences Ireland Unlimited Co | Polythérapie |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| RS65576B1 (sr) | 2017-11-24 | 2024-06-28 | Jubilant Episcribe Llc | Heterociklična jedinjenja kao inhibitori prmt5 |
| CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
| TWI861208B (zh) | 2019-09-10 | 2024-11-11 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物 |
| CN114423758B (zh) | 2019-09-13 | 2025-05-27 | 爱尔兰詹森科学公司 | 抗细菌化合物 |
| JP2022549881A (ja) * | 2019-09-26 | 2022-11-29 | ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド | マイコバクテリア感染症の処置のためのチアゾールカルボキサミド化合物およびその使用 |
| KR20220071199A (ko) | 2019-09-30 | 2022-05-31 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 4-퀴놀리논 항균 화합물 |
| CA3151712A1 (en) | 2019-09-30 | 2021-04-08 | Jerome Emile Georges Guillemont | Cytochrome bd inhibitors as anti-bacterial agents for the treatment of tuberculosis |
| WO2022194803A1 (en) | 2021-03-16 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CA3211592A1 (en) * | 2021-03-17 | 2022-09-22 | Jerome Emile Georges Guillemont | Antibacterial compounds |
| MX2023010941A (es) | 2021-03-17 | 2023-11-28 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CA3234515A1 (en) | 2021-10-28 | 2023-05-04 | Jose Manuel Bartolome-Nebreda | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9509673A (pt) | 1994-11-15 | 1997-09-30 | Upjohn Co | Compostos e uso dos mesmos |
| US6090820A (en) | 1995-05-11 | 2000-07-18 | Pharmacia & Upjohn Company | Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones |
| SI1527050T1 (sl) | 2002-07-25 | 2010-08-31 | Janssen Pharmaceutica Nv | Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| MA27360A1 (fr) | 2004-11-23 | 2005-06-01 | Brahim Bennani | Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux |
| CA2672960A1 (en) | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
| CL2008001631A1 (es) | 2007-06-06 | 2009-01-02 | Smithkline Beecham Corp | Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih. |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| CN101965353B (zh) | 2008-03-26 | 2014-12-17 | 丹诺医药(苏州）有限公司 | 共价连接到取代苯基噁唑烷酮的双环硝基咪唑类 |
| EP2353008A2 (en) | 2008-09-22 | 2011-08-10 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| JP2012514044A (ja) | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 |
| IN2012DN04917A (enExample) | 2009-11-05 | 2015-09-25 | Univ Notre Dame Du Lac | |
| RU2576662C2 (ru) * | 2010-03-18 | 2016-03-10 | Энститю Пастер Корея | Противоинфекционные соединения |
| WO2012143796A2 (en) | 2011-04-21 | 2012-10-26 | Institut Pasteur Korea | Anti-inflammation compounds |
| US8569283B2 (en) | 2011-09-01 | 2013-10-29 | Valentina Molteni | Compounds and compositions as c-Kit kinase inhibitors |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| HRP20170411T1 (hr) | 2012-03-02 | 2017-06-16 | Genentech, Inc. | Amido spirocilični amidni i sulfonamidni derivati |
| KR101918469B1 (ko) | 2012-06-04 | 2018-11-15 | 한국화학연구원 | 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| JP6483610B2 (ja) * | 2012-07-18 | 2019-03-13 | ユニバーシティ オブ ノートルダム デュ ラック | ５，５−ヘテロ芳香族抗感染症化合物 |
| WO2014023814A1 (en) * | 2012-08-10 | 2014-02-13 | Janssen R&D Ireland | New antibacterial compounds |
| KR101650716B1 (ko) | 2012-11-22 | 2016-08-24 | 한국화학연구원 | 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물 |
| WO2015014993A2 (en) | 2013-08-02 | 2015-02-05 | Institut Pasteur Korea | Anti-infective compounds |
| KR101564425B1 (ko) | 2013-11-26 | 2015-10-30 | 한국화학연구원 | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 |
| CN105524058B (zh) * | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| CN107249691A (zh) | 2014-11-03 | 2017-10-13 | 加利福利亚大学董事会 | 用于肺结核治疗的多药疗法 |
| MD3316969T2 (ro) | 2015-07-02 | 2022-07-31 | Janssen Sciences Ireland Unlimited Co | Compuși antibacterieni |
| EP3472152A1 (en) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacte rials |
| MA45377A (fr) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Co | Composés hétérocycliques en tant qu'agents antibacteriens |
| MA47676A (fr) | 2017-03-01 | 2021-06-02 | Janssen Sciences Ireland Unlimited Co | Polythérapie |
-
2017
- 2017-06-15 MA MA045377A patent/MA45377A/fr unknown
- 2017-06-15 KR KR1020197000960A patent/KR20190017948A/ko not_active Ceased
- 2017-06-15 AU AU2017286368A patent/AU2017286368B2/en not_active Ceased
- 2017-06-15 EP EP17729877.5A patent/EP3472158A1/en not_active Withdrawn
- 2017-06-15 US US16/309,725 patent/US11179396B2/en not_active Expired - Fee Related
- 2017-06-15 JP JP2018565675A patent/JP2019518046A/ja active Pending
- 2017-06-15 MX MX2018015656A patent/MX2018015656A/es unknown
- 2017-06-15 CN CN201780037229.4A patent/CN109476657A/zh active Pending
- 2017-06-15 EA EA201990043A patent/EA201990043A1/ru unknown
- 2017-06-15 CA CA3026010A patent/CA3026010A1/en not_active Abandoned
- 2017-06-15 BR BR112018076126-5A patent/BR112018076126A2/pt not_active Application Discontinuation
- 2017-06-15 WO PCT/EP2017/064652 patent/WO2017216281A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518050A5 (enExample) | ||
| JP2018519302A5 (enExample) | ||
| JP2024521979A5 (enExample) | ||
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| JP2018524339A5 (enExample) | ||
| JP2017524025A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2017527532A5 (enExample) | ||
| JP2019526596A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| PT76336B (de) | Cephalosporinderivate und verfahren zu ihrer herstellung | |
| JP2019529444A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| CN108025191A (zh) | 治疗癌症的方法 | |
| JP2019527724A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| CA3155875A1 (en) | BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE | |
| JP2015522592A5 (enExample) | ||
| UA81640C2 (ru) | Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе | |
| KR940702491A (ko) | 옥사졸리돈 유도체 | |
| KR101536488B1 (ko) | 이미다졸 유도체, 그의 제조 방법 및 용도 | |
| RU2007125130A (ru) | Применение атазанавира для улучшения фармакокинетики лекарственных средств, метаболизируемых ugt1a1 | |
| JP2022536043A5 (enExample) | ||
| HUP9702481A2 (hu) | Új N-benzil-piperazin-vegyületek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények |